Renaissance Capital logo

Gamida Cell Priced, Nasdaq: GMDA

Phase 3 biotech developing stem cell therapies for hematologic malignancies.

Industry: Health Care

First Day Return: +5.5%

Industry: Health Care

We are a clinical stage biopharmaceutical company leveraging our proprietary technology to develop cell therapies that are designed to cure cancer and rare, serious hematologic diseases. While cell therapies have the potential to address a variety of diseases, they are limited by availability of donor cells, matching a donor to the patient, and the decline in donor cell functionality when expanding the cells to achieve a therapeutic dose. We have leveraged our nicotinamide-, or NAM-, based cell expansion technology to develop a pipeline of products designed to address the limitations of cell therapies. Our proprietary technology allows for the proliferation of donor cells while maintaining the cells’ functional therapeutic characteristics, providing a treatment alternative for patients.
more less

Gamida Cell (GMDA) Performance